Shionogi Agrees to Acquire IntraBio for $2 Billion
Shionogi agreed to acquire IntraBio for $2.0 billion upfront, adding the oral levacetylleucine franchise and a rare-neurology pipeline. Recent approvals establish a commercial base, while adoption, reimbursement and integration will determine whether the price…
